Mutations in the phosphorylation sites of SARS-CoV-2 encoded nucleocapsid protein and structure model of sequestration by protein 14-3-3 von Tung, H.Y. Lim, Limtung, Pierre

Volltext

Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninf... von Kim, S.T., Kang, J.H., Lee, J., Lee, H.W., Oh, S.Y., Jang, J.S., Lee, M.A., Sohn, B.S., Yoon, S.Y., Choi, H.J., Hong, J.H., Kim, M.-J., Kim, S., Park, Y.S., Park, J.O., Lim, H.Y.

Volltext

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients von Kim, S.T., Banks, K.C., Pectasides, E., Kim, S.Y., Kim, K., Lanman, R.B., Talasaz, A., An, J., Choi, M.G., Lee, J.H., Sohn, T.S., Bae, J.M., Kim, S., Park, S.H., Park, J.O., Park, Y.S., Lim, H.Y., Kim, N.K.D., Park, W., Lee, H., Bass, A.J., Kim, K., Kang, W.K., Lee, J.

Volltext

Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma von Kang, Y.-K., Yau, T., Park, J.-W., Lim, H.Y., Lee, T.-Y., Obi, S., Chan, S.L., Qin, S.K., Kim, R.D., Casey, M., Chen, C., Bhattacharyya, H., Williams, J.A., Valota, O., Chakrabarti, D., Kudo, M.

Volltext

Off-design performance of a louvered fin-tube heater core in an automotive climate control system von Bhaiyat, T.I., Schekman, S., Lim, H.Y., Jeon, Y.H., Kim, T.

Volltext

Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma von Koh, Y., Lim, H.Y., Ahn, J.H., Lee, J.-L., Rha, S.Y., Kim, Y.J., Kim, T.M., Lee, S.-H.

Volltext

Identification of Triple-negative and Basal-like Canine Mammary Carcinomas using Four Basal Markers von Kim, N.H., Lim, H.Y., Im, K.S., Kim, J.H., Sur, J.-H.

Volltext

2353 Data from a phase Ib/II trial of the oral c-Met inhibitor tepotinib (MSC2156119J) as first-line therapy in Asian patients with advanced hepatocellular carcinoma von Qin, S, Lim, H.Y, Ryoo, B.Y, Li, C, Xiong, H, Ihling, C, Cheng, A.L

Volltext

P0231 : Effect of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma generated by hydrodynamic injectio... von Kim, M.N, Ro, S.W, Kim, Do Y, Kim, Da Y, Park, J.H, Lim, H.Y, Han, K.-H

Volltext

2318 Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer von Jung, K.S, Song, H.N, Yoo, K.H, Cho, J, Kim, S.T, Lee, J, Park, S.H, Park, Y.S, Lim, H.Y, Kang, W.K, Park, J.O

Volltext

217 Results of a phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with advanc... von Kang, Y.K, Ryoo, B.Y, Kim, T.Y, Lee, K.H, Lim, H.Y, Lee, S.J, Ikeda, M, Okusaka, T, Nadano, S, Lin, C.C, Poon, T.P, Yen, C.J, McCoon, P, Neumann, F, Vishwantahan, K, DuPont, R, Lyne, P

Volltext

501 Immunological STAT3 knockdown associated with anti-tumor activity in pre-clinical models translates to clinical samples, suggesting immune modulation contributes to the clinica... von McCoon, P, Woessner, R, DuPont, R, Bell, K, Collins, M, Pablo, L, Lawson, D, Nadella, P, Jacobs, V, Womack, C, Reimer, C, Hong, D, Nemunaitis, J, Kang, Y.K, Kim, T.Y, Lim, H.Y, Okusaka, T, Nadano, S, Lin, C.C, Lyne, P

Volltext

A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gast... von Park, S.H., Lim, D.H., Sohn, T.S., Lee, J., Zang, D.Y., Kim, S.T., Kang, J.H., Oh, S.Y., Hwang, I.G., Ji, J.H., Shin, D.B., Yu, J.I., Kim, K.-M., An, J.Y., Choi, M.G., Lee, J.H., Kim, S., Hong, J.Y., Park, J.O., Park, Y.S., Lim, H.Y., Bae, J.M., Kang, W.K.

Volltext

294 Heat Shock Protein-90 (Hsp-90) Inhibitor, 17-AAG Blocks Transforming Growth Factor (TGF)-β1 Induced Epithelialmesenchymal Transition (EMT) in A549 Cells von Kim, Y.S, Hong, J.O, Jang, H.L, Lee, J, Park, S.H, Park, Y.S, Lim, H.Y, Kang, W.K, Park, J.O

Volltext

A multi-centre review of mobilisation strategies post upfront VCD induction in multiple myeloma: is G-CSF alone sufficient? von Chua, C.C, Lim, H.Y, Chai, K.L, Campbell, P, King, H, Dowsing, C, Bergin, K, Muir, S, Gibbs, S, Grigg, A

Volltext

Loss of arterial resident LYVE-1 expressing macrophages exacerbates atherosclerosis von Ang, O., Lim, H.Y., Lim, S.Y., Lau, J., Azhar, S.H.M., Thiam, C.H., Angeli, V.

Volltext

6576 POSTER Phase II Safety Study of the Oral Multikinase Inhibitor Regorafenib (BAY 73-4506) as Second-line Therapy in Patients With Hepatocellular Carcinoma von Bolondi, L, Tak, W.Y, Gasbarrini, A, Santoro, A, Colombo, M, Lim, H.Y, Mazzaferro, V, Wiest, R, Reig, M, Bruix, J

Volltext

1035P Phase I dose escalation study of IMC-002, a novel anti-CD47 monoclonal antibody, in patients with advanced solid tumors von Lim, H.Y., Ahn, J.S., Park, J.O., Yong Hong, J., Seon, H., Lee, J.K., LEE, S.Y., Kim, H.T.

Volltext

760 Melanin may mediate visible light induced phototoxicity in darker skin types von Lim, H.Y., Kerns, M.L., Kang, S., Chien, A.L.

Volltext

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma von Abou-Alfa, G.K., Qin, S., Ryoo, B.-Y., Lu, S.-N., Yen, C.-J., Feng, Y.-H., Lim, H.Y., Izzo, F., Colombo, M., Sarker, D., Bolondi, L., Vaccaro, G., Harris, W.P., Chen, Z., Hubner, R.A., Meyer, T., Sun, W., Harding, J.J., Hollywood, E.M., Ma, J., Wan, P.J., Ly, M., Bomalaski, J., Johnston, A., Lin, C.-C., Chao, Y., Chen, L.-T.

Volltext